Systematic synergy modeling: Understanding drug synergy from a systems biology perspective

BMC Systems Biology

Volumn 9, Issue 1, 2015, Pages

  Chen, Di ^a   Liu, Xi ^a   Yang, Yiping ^a   Yang, Hongjun ^b   Lu, Peng ^a,b  

^a INSTITUTE OF AUTOMATION   (China)

^b INSTITUTE OF CHINESE MATERIA MEDICA   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MODEL; DRUG POTENTIATION; HUMAN; PROCEDURES; PROTEIN ANALYSIS; SYSTEMS BIOLOGY;

DRUG SYNERGISM; HUMANS; MODELS, BIOLOGICAL; PROTEIN INTERACTION MAPPING; SYSTEMS BIOLOGY;

EID: 84941637635     PISSN: None     EISSN: 17520509     Source Type: Journal    
DOI: 10.1186/s12918-015-0202-y     Document Type: Review

References (76)

1. Bigioni M, Benzo A, Irrissuto C, Lopez G, Curatella B, Maggi CA, et al. Antitumour effect of combination treatment with Sabarubicin (MEN 10755) and cis-platin (DDP) in human lung tumour xenograft. Cancer Chemother Pharmacol. 2008;62:621-9.
2. Lenz TL, Hilleman DE. Aggrenox: a fixed-dose combination of aspirin and dipyridamole. Ann Pharmacother. 2000;34:1283-90.
3. Breeze S. Novel HIV-1 treatment Stribild gains regulatory approval. Expert Rev Clin Pharmacol. 2012;5:613.
4. Liu Y, Hu B, Fu C, Chen X. DCDB: drug combination database. Bioinformatics. 2010;26:587-8.
5. Albers GW, Amarenco P. Combination Therapy With Clopidogrel and Aspirin. Stroke. 2001;32:2948-9.
6. Bezin J, Pariente A, Lassalle R, Dureau-Pournin C, Abouelfath A, Robinson P, et al. Use of the recommended drug combination for secondary prevention after a first occurrence of acute coronary syndrome in France. Eur J Clin Pharmacol. 2014;70:429-36.
7. Singh S, Bouzinbi N, Chaturvedi V, Godreuil S, Kremer L. In vitro evaluation of a new drug combination against clinical isolates belonging to the Mycobacterium abscessus complex. Clin Microbiol Infect. 2014;20:O1124-7.
8. Lee HZ, Miller BW, Kwitkowski VE, Ricci S, DelValle P, Saber H, et al. U.S. Food and drug administration approval: obinutuzumab in combination with chlorambucil for the treatment of previously untreated chronic lymphocytic leukemia. Clin Cancer Res. 2014;20:3902-7.
9. Patankar NA, Pritchard J, van Grinsven M, Osooly M, Bally MB. Topotecan and doxorubicin combination to treat recurrent ovarian cancer: the influence of drug exposure time and delivery systems to achieve optimum therapeutic activity. Clin Cancer Res. 2013;19:865-77.
10. Sucher NJ. Searching for synergy in silico, in vitro and in vivo. Synergy. 2014;1:30-43.
11. Loewe S. Die Mischiarnei. Klin Wochenschr. 1927;6:1077-85.
12. Loewe S. The problem of synergism and antagonism of combined drugs. Arzneimittelforschung. 1953;3:285-90.
13. Bliss CI. The toxicity of poison applied jointly. Ann Appl Biol. 1939;28:585-615.
14. Chou TC. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res. 2010;70:440-6.
15. Chou TC. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev. 2006;58:621-81.
16. Tallarida RJ. Quantitative methods for assessing drug synergism. Genes & cancer. 2011;2:1003-8.
17. Doern CD. When does 2 plus 2 equal 5? A review of antimicrobial synergy testing. J Clin Microbiol. 2014;52:4124-8.
18. Leung EL, Cao ZW, Jiang ZH, Zhou H, Liu L. Network-based drug discovery by integrating systems biology and computational technologies. Brief Bioinform. 2013;14:491-505.
19. Csermely P, Agoston V, Pongor S. The efficiency of multi-target drugs: the network approach might help drug design. Trends Pharmacol Sci. 2005;26:178-82.
20. Lu JJ, Pan W, Hu YJ, Wang YT. Multi-target drugs: the trend of drug research and development. PLoS One. 2012;7:e40262.
21. Schrattenholz A, Groebe K, Soskic V. Systems biology approaches and tools for analysis of interactomes and multi-target drugs. Methods Mol Biol. 2010;662:29-58.
22. Feala JD, Cortes J, Duxbury PM, Piermarocchi C, McCulloch AD, Paternostro G. Systems approaches and algorithms for discovery of combinatorial therapies. Wiley Interdiscip Rev Syst Biol Med. 2010;2:181-93.
23. Galizzi JP, Lockhart BP, Bril A. Applying systems biology in drug discovery and development. Drug Metabol Drug Interact. 2013;28:67-78.
24. Li P, Huang C, Fu YX, Wang JA, Wu ZY, Ru JL, et al. Large-scale exploration and analysis of drug combinations. Bioinformatics. 2015;31:2007-16.
25. Berg EL. Systems biology in drug discovery and development. Drug Discov Today. 2014;19:113-25.
26. Zimmermann GR, Lehar J, Keith CT. Multi-target therapeutics: when the whole is greater than the sum of the parts. Drug Discov Today. 2007;12:34-42.
27. Li Y, Agarwal P. A Pathway-Based View of Human Diseases and Disease Relationships. Plos ONE. 2009;4:e4346.
28. Li S, Zhang B, Zhang N. Network target for screening synergistic drug combinations with application to traditional Chinese medicine. BMC Syst Biol. 2011;5 Suppl 1:S10.
29. Vitali F, Mulas F, Marini P, Bellazzi R. Network-based target ranking for polypharmacological therapies. J Biomed Inform. 2013;46:876-81.
30. Huang L, Li F, Sheng J, Xia X, Ma J, Zhan M, et al. DrugComboRanker: drug combination discovery based on target network analysis. Bioinformatics. 2014;30:i228-36.
31. Wang YY, Xu KJ, Song J, Zhao XM. Exploring drug combinations in genetic interaction network. BMC bioinformatics. 2012;13 Suppl 7:S7.
32. Ren G, Liu Z. NetCAD: a network analysis tool for coronary artery disease-associated PPI network. Bioinformatics. 2013;29:279-80.
33. Wan FC, Cui YP, Wu JT, Wang JM, -Z Liu Q, Gao ZL. The PPI network and cluster ONE analysis to explain the mechanism of bladder cancer. Eur Rev Med Pharmacol Sci. 2013;17:618-23.
34. Wu B, Xie J, Du Z, Wu J, Zhang P, Xu L, et al. PPI network analysis of mRNA expression profile of ezrin knockdown in esophageal squamous cell carcinoma. Biomed Res Int. 2014;2014:651954.
35. Viswanathan GA, Seto J, Patil S, Nudelman G, Sealfon SC. Getting started in biological pathway construction and analysis. PLoS Comput Biol. 2008;4, e16.
36. Jia J, Zhu F, Ma X, Cao Z, Li Y, Chen YZ. Mechanisms of drug combinations: interaction and network perspectives. Nat Rev Drug Discov. 2009;8:111-28.
37. Polynikis A, Hogan SJ, di Bernardo M. Comparing different ODE modelling approaches for gene regulatory networks. J Theor Biol. 2009;261:511-30.
38. Elias J, Dimitrio L, Clairambault J, Natalini R. The dynamics of p53 in single cells: physiologically based ODE and reaction-diffusion PDE models. Phys Biol. 2014;11:045001.
39. Khan FM, Schmitz U, Nikolov S, Engelmann D, Putzer BM, Wolkenhauer O, et al. Hybrid modeling of the crosstalk between signaling and transcriptional networks using ordinary differential equations and multi-valued logic. Biochim Biophys Acta. 1844;2014:289-98.
40. Araujo RP, Petricoin EF, Liotta LA. A mathematical model of combination therapy using the EGFR signaling network. Biosystems. 2005;80:57-69.
41. Nelander S, Wang W, Nilsson B, She QB, Pratilas C, Rosen N, et al. Models from experiments: combinatorial drug perturbations of cancer cells. Mol Syst Biol. 2008;4:216.
42. Sun X, Bao J, Nelson KC, Li KC, Kulik G, Zhou X. Systems Modeling of Anti-apoptotic Pathways in Prostate Cancer: Psychological Stress Triggers a Synergism Pattern Switch in Drug Combination Therapy. PLoS Comput Biol. 2013;9:e1003358.
43. Miller ML, Molinelli EJ, Nair JS, Sheikh T, Samy R, Jing X, et al. Drug synergy screen and network modeling in dedifferentiated liposarcoma identifies CDK4 and IGF1R as synergistic drug targets. Sci signal. 2013;6:ra85.
44. Klinger B, Sieber A, Fritsche-Guenther R, Witzel F, Berry L, Schumacher D, et al. Network quantification of EGFR signaling unveils potential for targeted combination therapy. Mol Syst Biol. 2013;9:673.
45. Yan H, Zhang B, Li S, Zhao Q. A formal model for analyzing drug combination effects and its application in TNF-alpha-induced NFkappaB pathway. BMC Syst Biol. 2010;4:50.
46. Azmi AS, Banerjee S, Ali S, Wang Z, Bao B, Beck FWJ, et al. Network Modeling of MDM2 Inhibitor-Oxaliplatin Combination Reveals Biological Synergy in wt-p53 solid tumors. Oncotarget. 2011;2:15.
47. Li Z, Zhou H, Lu Y, Colatsky T. A Critical Role for Immune System Response in Mediating Anti-influenza Drug Synergies Assessed by Mechanistic Modeling. CPT Pharmacometrics Syst Pharmacol. 2014;3, e135.
48. Milo R, Shen-Orr S, Itzkovitz S, Kashtan N, Chklovskii D, Alon U. Network motifs: simple building blocks of complex networks. Science. 2002;298:824-7.
49. Wong E, Baur B, Quader S, Huang CH. Biological network motif detection: principles and practice. Brief Bioinform. 2012;13:202-15.
50. Han Z, Vondriska TM, Yang L, Robb MacLellan W, Weiss JN, Qu Z. Signal transduction network motifs and biological memory. J Theor Biol. 2007;246:755-61.
51. Tyson JJ, Novak B. Functional motifs in biochemical reaction networks. Annu Rev Phys Chem. 2010;61:219-40.
52. Fioravanti F, Helmer-Citterich M, Nardelli E. Modeling gene regulatory network motifs using Statecharts. BMC bioinformatics. 2012;13 Suppl 4:S20.
53. Zhang Y, Smolen P, Baxter DA, Byrne JH. Computational analyses of synergism in small molecular network motifs. PLoS Comput Biol. 2014;10, e1003524.
54. Yin N, Ma W, Pei J, Ouyang Q, Tang C, Lai L. Synergistic and Antagonistic Drug Combinations Depend on Network Topology. PLoS ONE. 2014;9, e93960.
55. Axelrod M, Gordon VL, Conaway M, Tarcsafalvi A, Neitzke DJ, Gioeli D, et al. Combinatorial drug screening identifies compensatory pathway interactions and adaptive resistance mechanisms. Oncotarget. 2013;4:622-35.
56. Dent P, Curiel DT, Fisher PB, Grant S. Synergistic combinations of signaling pathway inhibitors: Mechanisms for improved cancer therapy. Drug Resist Updat. 2009;12:65-73.
57. Azmi AS, Wang Z, Philip PA, Mohammad RM, Sarkar FH. Proof of concept: network and systems biology approaches aid in the discovery of potent anticancer drug combinations. Mol Cancer Ther.2010;9:3137-44.
58. Reddy AS, Zhang S. Polypharmacology: drug discovery for the future. Expert Rev Clin Pharmacol. 2013;6:41-7.
59. Parikh JR, Klinger B, Xia Y, Marto JA, Bluthgen N. Discovering causal signaling pathways through gene-expression patterns. Nucleic Acids Res. 2010;38:W109-17.
60. Janes KA, Lauffenburger DA. Models of signalling networks - what cell biologists can gain from them and give to them. J Cell Sci. 2013;126:1913-21.
61. Zhao XM, Iskar M, Zeller G, Kuhn M, van Noort V, Bork P. Prediction of drug combinations by integrating molecular and pharmacological data. PLoS Comput Biol. 2011;7, e1002323.
62. Chen L, Li BQ, Zheng MY, Zhang J, Feng KY, Cai YD. Prediction of effective drug combinations by chemical interaction, protein interaction and target enrichment of KEGG pathways. Biomed Res Int. 2013;2013:723780.
63. Cui Y, Paules RS. Use of transcriptomics in understanding mechanisms of drug-induced toxicity. Pharmacogenomics. 2010;11:573-85.
64. Zhao S, Iyengar R. Systems pharmacology: network analysis to identify multiscale mechanisms of drug action. Annu Rev Pharmacol Toxicol. 2012;52:505-21.
65. Kaur G, Rajput B. Comparative analysis of the omics technologies used to study antimonial, amphotericin B, and pentamidine resistance in leishmania. J Parasitol Res. 2014;2014:726328.
66. Lee KJ, Yin W, Arafat D, Tang Y, Uppal K, Tran V, et al. Comparative transcriptomics and metabolomics in a rhesus macaque drug administration study. Front Cell Dev Biol. 2014;2:54.
67. Stratton MR. Exploring the genomes of cancer cells: progress and promise. Science. 2011;331:1553-8.
68. Tieri P, Zhou X, Zhu L, Nardini C. Multi-omic landscape of rheumatoid arthritis: re-evaluation of drug adverse effects. Front Cell Dev Biol. 2014;2:59.
69. Lamb J, Crawford ED, Peck D, Modell JW, Blat IC, Wrobel MJ, et al. The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science. 2006;313:1929-35.
70. Coughlin SS. Toward a road map for global -omics: a primer on -omic technologies. AM J Epidemiol. 2004;180:1188-95.
71. Wu Z, Zhao XM, Chen L. A systems biology approach to identify effective cocktail drugs. BMC Syst Biol. 2010;4 Suppl 2:S7.
72. Jin G, Zhao H, Zhou X, Wong ST. An enhanced Petri-net model to predict synergistic effects of pairwise drug combinations from gene microarray data. Bioinformatics. 2011;27:i310-6.
73. Zhao J, Zhang XS, Zhang S. Predicting cooperative drug effects through the quantitative cellular profiling of response to individual drugs. CPT Pharmacometrics Syst Pharmacol. 2014;3, e102.
74. Jansen G, Lee AY, Epp E, Fredette A, Surprenant J, Harcus D, et al. Chemogenomic profiling predicts antifungal synergies. Mol Syst Biol. 2009;5:338.
75. Winter GE, Rix U, Carlson SM, Gleixner KV, Grebien F, Gridling M, et al. Systems-pharmacology dissection of a drug synergy in imatinib-resistant CML. Nat Chem Biol. 2012;8:905-12.
76. Cokol M, Chua HN, Tasan M, Mutlu B, Weinstein ZB, Suzuki Y, et al. Systematic exploration of synergistic drug pairs. Mol Syst Biol. 2011;7:544.